Oncogenic constitutively active RAS mutants are found in 30% of all human cancers. In addition to acquisition of point mutations, functional activation of RAS may occur as a part of altered intracellular signal transduction associated with oncogenic transformation. Since RAS appears as a common signal transduction crossroad for various regulatory pathways, there is hardly an aspect of malignant phenotype that was not described as being affected by its activation (reviewed in Malumbres and Barbacid, 2003; and in Campbell and Der, 2004) .
Oncogenic constitutively active RAS mutants are found in 30% of all human cancers. In addition to acquisition of point mutations, functional activation of RAS may occur as a part of altered intracellular signal transduction associated with oncogenic transformation. Since RAS appears as a common signal transduction crossroad for various regulatory pathways, there is hardly an aspect of malignant phenotype that was not described as being affected by its activation (reviewed in Malumbres and Barbacid, 2003; and in Campbell and Der, 2004) .
Pleiotropic oncogenic properties of RAS are materialized through interaction with multiple downstream effector proteins, which, in turn, also have a solid established role in tumorigenesis. RAS-RAF interaction leads to the activation of RAF kinase and subsequent triggering of MEK-ERK cascade. RAS-PI3K interaction stimulates lipid kinase activity of the latter, resulting in the activation of a network of downstream effectors, which include AKT S6 kinase, several isoforms of PKC and RAC-GEFs. Binding of RAS to the proteins known as RAL-GEFs (RAL GDS, RGL1 and 2, RLF) triggers activation of RAS-related subfamily of small GTPases consisting of two homologous proteins, RAL-A and -B. Molecular mechanisms that imply RAL-mediated signaling in tumorigenesis are the least characterized compared to enormous amount of data accumulated on cancer connection of MEK/ERK and PI3K pathways. Nevertheless, recent works unequivocally indicate that contribution of RAL to the pathogenesis of cancer, in general, and to RAS-dependent cancerogenesis, specifically, was probably underestimated. It is, therefore, understandable why a fresh and comprehensive review by Feig (2003) on RAL-dependent signaling was entitled: 'Ral-GTPases: approaching their 15 min of fame'. In light of this, an elegant study by the Moscow (Russia) group led by A. Tatosyan w (Tchevkina et al., 2004) , which establishes a unique role of RAL-A in RAS-mediated metastasis, has appeared just in time.
In spite of a relatively good general understanding of RAS contribution to oncogenic transformation, the exact pathways involved in RAS-dependent metastasis are not completely elucidated. To address the role of separate branches of RAS downstream signaling in metastasis, Tchevkina et al. used a unique collection of transformed Syrian hamster embryo fibroblast cell lines generated over the years by G.I. Deichman in the Moscow Cancer Research Center. The collection includes both spontaneously and v-SRC-transformed cell lines with varying and well-characterized in vivo metastatic potential. One of these cell lines, v-SRCtransformed HET-SR, being highly metastatic when injected intravenously in syngeneic animals (experimental metastasis assay, EMA), displayed low metastatic potential when grown as a subcutaneous tumor (spontaneous metastasis assay, SMA). Spontaneous metastatic ability is generally considered as more relevant to the clinical disease as well as a more advanced step of tumor progression since prior to the hematogenous spreading, tumor cells need to penetrate into the bloodstream, exactly as it happens in the natural course of cancer. The difference of experimental and spontaneous metastatic potential HET-SR cells enabled the researches to design a clean experiment aimed to demonstrate whether introduction of activated H-RASV12 would be sufficient to increase specifically the metastatic properties of these cells and to get a clean answer: yes, spontaneous metastasis was enhanced B50-fold. The next step was to find out which of the RASmediated downstream pathways was/were responsible for such a dramatic increase of metastases rate. For this, instead of activated RAS, HET-SR cells were transduced with RAS mutants, H-RASV12S35, or H-RASV12C40, or H-RASV12G37, each activating only one of the three RAS effector pathways mediated by either RAF, or PI3K, or RALGDS, respectively. It turned out that only the RALGDS activating mutant was capable to confer enhanced metastatic properties. The unique role of RAL-A in mediating prometastatic abilities of activated RAS was further confirmed by suppression of H-RASV12G37-induced lung metastasis by dominant-negative RAL-A (S28N). Moreover, overexpression of constitutively active RAL-A in HET-SR cells elicited metastatic phenotype similar to the one triggered by H-RASV12G37. It should be noted, however, that the proportion of animals with more than 100 lung metastases was the highest in the H-RASV12-transduced group and the lowest in the activated RAL-A-transduced group, whereas dominant-negative RAL-A was unable to reduce the H-RASV12G37-triggered metastasis to the basal HET-SR level (Tchevkina et al., 2004, Figure 2a) . Therefore, although it is very likely that activation of RAL-A plays the major role in H-RAS-induced metastasis, the data clearly point to the involvement of additional molecular mechanisms both downstream and parallel to RALGDS. Indeed, a certain dependence of RAL prometastatic function on cooperation with other branches of RAS signaling was previously demonstrated (Ward et al., 2001) .
In the following series of experiments, Tchevkina et al. were able to demonstrate that not only turning on of RAL signaling triggered metastasis but turning it off led to metastasis suppression. Thus, overexpression of dominant-negative RAL-A was sufficient to inhibit hematogenous (experimental) metastasis in HET-SR as well as to abolish both experimental and spontaneous metastasis in HET-SR-LNM cells derived from a naturally occurring hamster metastatic tumor and, in contrast to HET-SR, displaying also intrinsically high metastatic potential in SMA. Comparison of the endogenous levels of activated RAL-A between moderately metastatic HET-SR and highly metastatic HET-SR-LNM revealed its significantly higher activity in the latter cells, hence further establishing the dose dependence of the cells' metastatic potential on the level of endogenous RAL activation. Importantly, prometastatic activity of RAL-A was not restricted to v-SRCtransformed cells and was also shown in spontaneously transformed and initially non-metastatic STHE hamster fibroblast cell line.
It should be mentioned, however, that the work by Tchevkina et al. is not the first one that points to the involvement of RAL signaling in metastasis. In 2001, the group of Kelly from NCI (Ward et al., 2001) , using NIH 3T3 and breast carcinoma cells, demonstrated the critical importance of RAL-GEF-mediated pathway for tumor invasiveness and metastasis. Having no influence on the in vitro morphology and only slightly inducing the ability to grow in soft agar, transfection of H-RASV12G37 drastically increased experimental metastasis of NIH 3T3 cells and their ability to invade Matrigel. Interestingly, whereas dominant-negative RAL-B mutant was able to inhibit the metastatic phenotype triggered by H-RASV12G37 in this cell system, overexpression of constitutively active RAL-B was neutral in this regard. In contrast, Tatosyan's group demonstrated significant metastatic potential of constitutively active RAL-A in a similar assay. This seeming discrepancy may be explained by a potential unique involvement of RAL-A and not of RAL-B in the metastatic process that is by itself an important conclusion.
Unfortunately, the work by Tchevkina et al. does not address the downstream mechanisms, which are specifically utilized by RAL to promote metastasis. Nevertheless, some answers may be potentially obtained from the literature. On the one hand, the relevant molecular pathways should probably be unique for RAL and not shared with RAF/MEK or PI3K branches of RAS signaling. On the other, the pathway of interest is likely to be less required for experimental than for spontaneous metastatic process. This view potentially excludes from the consideration such RAL properties as influence on cell survival (Chien and White, 2003) , proliferation or gene expression (for more details, see Feig, 2003; Campbell and Der, 2004) , and prompts to concentrate on RAL connection to invasiveness. Indeed, an added requirement for spontaneous metastasis compared to the experimental one is the ability of tumor cells to invade into the space of blood vessels (and also through basement membrane for naturally occurring cancers). This reasoning is also supported by experimental data demonstrating distinctive invasive phenotype of H-RASV12G37-induced metastases, which are presented as multiple macroscopic nodules accompanied by adjacent microscopic satellite tumors and nests of tumor cells within lung parenchyma. Moreover, experimental evidence points to H-RASV12G37 involvement in the late stages of metastatic process, specifically associated with the invasiveness of already established lesions (Ward et al., 2001) .
Several unique RAL downstream targets may contribute to the observed invasive phenotype. Although all major RAS downstream signaling pathways promote cytoskeleton reorganization, only RAL is capable of triggering filopodia formation by targeting filamin (Feig, 2003) . However, the potential role of this pathway was diminished by the observation that dominant-negative RAL-B efficiently inhibited metastatic ability of H-RASV12G37 without affecting the associated cell motility (Ward et al., 2001) . Another unique feature of RAL proteins is their involvement in vesicle sorting. This includes both endocytic (receptor-mediated endocytosis) and exocytic events (via interaction with Sec5) such as specific basolateral delivery of membrane components in epithelial cells and regulation of secretion (Feig, 2003) . In this regard, it is worth noting that RAL interaction partner, ARF6, which, like RAL itself, is involved in the regulation of membrane recycling and vesicle transport, was recently identified as an important factor of cell invasiveness participating in localized matrix degradation and Matrigel transmigration (Hashimoto et al., 2004) . Oncogene-stimulated overproduction of matrixdegrading proteinases, such as uPA, MMP2 and MMP9, is mediated via RAL-A/phospholipase D (PLD) pathway (Aguirre-Ghiso et al., 1999) . At the same time, H-RAS-induced activation of PLD depends on synergistic action of both RAL-A and ARF6 (Xu et al., 2003) . Hence, it is tempting to speculate that specific invasive phenotype of H-RASV12G37-transformed cells stems from RAL-mediated activation of basolateral transport of vesicles containing excessive amounts of matrix-degrading enzymes, thus causing redistribution of proteolytic activity in tumor stroma. Speculations, however, should be proven and the exact molecular mechanisms underlying RAL-dependent invasive phenotype need to be defined experimentally by systematic inactivation of the components of RAL downstream pathways employing, for example, RNA interference.
To conclude, the main significance of the work by the group of Tatosyan is that it established for the first time a direct correlation between RAL-A activity in the tumor and its metastatic potential. Moreover, the work has clearly demonstrated the possibility to modulate tumor metastatic potential by modulating RAL-A activity. Based on these results and taking into account a specific importance of RAL pathway for transformation of human cells (Hamad et al., 2002) , RAL is expected to become an important target for the development of novel anticancer therapeutics. As such, it seems to be approaching the fame that will last much longer than 15 min.
